GlassScriptPhysician profile
Vuy H Li
NPI 1629168372
$7,876.34
in general payments reported to CMS, 2019-2025
37 companies · $2,531 in 2025
The $2,531 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $1,046 · 2021: $686 · 2022: $648 · 2023: $1,388 · 2024: $836 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,701 · Travel and Lodging: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.38 |
| Travel and Lodging | $1,053.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,550.67 | 2019-2025 | Aveir, Confirm Rx, Cardiomems |
| Boston Scientific Corporation | $1,500.78 | 2019-2025 | Emblem Mri S-Icd, Watchman Flx, General - Therapies |
| Astrazeneca Pharmaceuticals LP | $612.89 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Cardiofocus, INC. | $450.46 | 2020 | |
| Novartis Pharmaceuticals Corporation | $441.15 | 2019-2025 | |
| Pfizer INC. | $351.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $288.78 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $189.33 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.21 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $113.06 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $103.05 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $95.60 | 2019-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $90.18 | 2023-2025 | |
| Novo Nordisk INC | $88.35 | 2023-2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $87.94 | 2022-2024 | Onpattro |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vuy Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.